Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: an Updated Meta-Analysis of 20 Randomized Controlled Trials and Subgroup Analyses

Aim: Multi-targeted antiangiogenic tyrosine kinase inhibitors (MATKIs) have been studied by many randomized controlled trials (RCTs) in treatments of advanced non-small cell lung cancer (NSCLC). Here we performed a timely meta-analysis to summarize the most up-to-date evidences and examined the effect of covariates on outcomes through subgroup analyses.